高级检索
当前位置: 首页 > 详情页

Uterine smooth muscle tumor of uncertain malignant potential (STUMP) with coagulative necrosis: a comprehensive clinicopathologic study of 10 cases with long-term follow up

| 认领 | 导出 |

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China [2]Department of Obstetrics and Gynecology, Beijing Friendship Hospital, Capital Medical University, Beijing, China [3]Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
出处:
ISSN:

关键词: Uterine smooth muscle tumor of uncertain malignant potential coagulative tumor cell necrosis p16 p53 Ki-67

摘要:
To observe the importance of coagulative tumor cell necrosis (CTCN) in the diagnosis of uterine smooth muscle tumors and to find ancillary methods that could help identify cases with potential of recurrence. Ten cases were selected. Complete clinical dates and pathological findings were reviewed for each case. Immunohistochemical stains for p16, p53, DOG-1, CD117 and Ki-67 were performed. The follow-up data was all available. Large areas of geographical CTCN were noted in 3 cases and multiple small foci of CTCN were found in 7 cases. Cytological atypia was absent to mild. The highest mitosis was 5 MFs/10 HPFs. One case was treated with leuprolide acetate before operation. P16, P53 and DOG-1 that were negative in other cases were diffusely positive in this case which also had a higher proliferation index (Ki-67) than others. This case developed recurrence at 27 months after the initial operation. This study suggests that a minority of STUMPs with CTCN will recur latterly. The combined results of P16, p53 and Ki-67 stains are useful to identify the STUMPs with an increased risk of recurrence supporting earlier observations. DOG1 may be a useful marker for STUMPs with potential malignancy. Our study adds to the limited experience of the clinical behavior of uterine smooth muscle tumors with coagulative necrosis treated with Leuprolide acetate (GnRH agonist).

语种:
WOS:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 病理学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学 4 区 病理学
JCR分区:
出版当年[2014]版:
Q3 PATHOLOGY Q3 ONCOLOGY
最新[2023]版:
Q3 PATHOLOGY Q4 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2014版] 出版当年五年平均[2010-2014] 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者单位: [1]Department of Pathology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
通讯作者:
通讯机构: [3]Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China [*1]Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)